Fig. 5
From: CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity
CAR exosomes have notable antitumour activity in vivo. a Tumour volumes of MDA-MB-231 (left), HCC827 (middle) and SK-BR-3 (right) tumour xenografts after treatment with the indicated treatment, n = 8. b, c Tumour volumes of MDA-MB-231 (b) and SK-BR-3 (c) tumour xenografts after treatment with the indicated CAR exosome treatment with or without blocking recombinant antigen, n = 8. d Cancer cell lines or patient-derived tumour tissue fragments established as subcutaneous xenografts (n = 8) and treated with weekly doses of CAR exosomes (100 μg). Substantial TGI was observed in lung cancer models treated with CAR-EXO-CTX (black bars) and in HER2-positive breast and ovary cancer models treated with CAR-EXO-TTZ (grey bars). Arrows indicate the treatment point (a–c). Data are means ± s.e.m. (a–c). P values are from a two-way ANOVA followed by Bonferroni post-test (a–c). Source data (a–d) are provided as a Source Data file
